Important Roles of Cellular MicroRNA miR-155 in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection

Mariko Tomita, Mariko Tomita

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) is the pathogen that causes the aggressive and lethal malignancy of CD4+ T-lymphocytes called adult T-cell leukemia/lymphoma (ATLL). MicroRNAs (miRNAs), a class of short, noncoding RNAs, regulate gene expression by targeting mRNAs for translational repression or cleavage. miRNAs are involved in many aspects of cell biology linked with formation of several cancer phenotypes. However, the relation between miRNAs and pathologic implication in ATLL is not well elucidated. Here, we evaluated the roles of cellular miRNAs in ATLL caused by HTLV-1. We found that the expression of miR-155 was increased in HTLV-1-positive T-cell lines. miR-155 expression was enhanced by Tax and binding of transcription factors, NF- κ B and AP-1, on the transcription binding sites of miR-155 gene promoter region is important to increase the expression of miR-155 by Tax. Transfection of anti-miR-155 inhibitor, which inhibits the function of miR-155, inhibited the growth of HTLV-1-positive T-cell lines. On the other hand, the growth of HTLV-1-negative T-cell lines was not changed by transfection of anti-miR-155. Forced expression of miR-155 enhanced the growth of HTLV-1-positive T-cell lines. These findings indicate that targeting the functions of miRNAs is a novel approach to the prevention or treatment of ATLL.

Figures

Figure 1
Figure 1
High expression of miR-155 in HTLV-1-positive T-cell lines. The expression of miR-155 in HTLV-1-positive (HTLV-1(+)) and in HTLV-1-negative T-cell lines (HTLV-1(−)) was analyzed by TaqMan real-time RT-PCR. Values are displayed as fold induction of miR-155 expression relative to that in Jurkat cells. Values are the mean ± SD from three separate experiments. Numbers on the MT-2, C5/MJ, and ED-40515(−) represent the real values.
Figure 2
Figure 2
The expression of miR-155 was induced by Tax in T cells. Tax-inducible cell line, JPX-9 cells were cultured with CdCl2 (20 μM) for indicated time periods. (a) Tax expression in CdCl2-treated JPX-9 cells. Cell lysates were prepared from CdCl2-treated JPX-9 cells at the indicated time points. Tax protein expression after CdCl2 treatments was determined by western blot. Actin protein expression served as a loading control. (b) miR-155 expression was analyzed by real-time RT-PCR. miR-155 expression is shown as a fold induction relative to the values measured at 0 h. Values are the mean ± SD from three separate experiments.
Figure 3
Figure 3
miR-155 promoter activity was increased by Tax through both NF-κB and AP-1 activation. (a) Putative transcription factor binding sites in the miR-155 promoter are presented in the left panel. Luciferase reporter plasmids with either wild-type or mutant miR-155 gene promoter together with either Tax expression plasmid (Tax (+)) or empty vector (Tax (−)) were transfected into Jurkat cells. Then the cells were incubated for 48 h. Luciferase reporter activity is shown as a fold induction relative to the levels measured in the cells transfected with the empty vector (Tax (−)). (b) Jurkat cells were transfected with following plasmids: luciferase reporter plasmids of wild-type miR-155 promoter together with either Tax wild type (WT), M22, 703 expression plasmids, or empty vector. Luciferase activity was analyzed 48 h later. Values are the mean ± SD from three separate experiments.
Figure 4
Figure 4
NF-κB signaling is important for miR-155 expression in HTLV-1-positive T cells. (a) DNA-binding activities of proteins to the promoter region of miR-155 gene in HTLV-1-positive and -negative T-cell lines were evaluated by EMSA. The NF-κB oligonucleotide probe containing the NF-κB-binding site from miR-155 gene was used. Arrow shows specific DNA-protein complexes. (b) The specificity of NF-κB-DNA binding was analyzed in MT-2 cells. Competition assay with cold competitors of wild type (WT) or mutated (Mut) probe showed the specificity of the protein-DNA-binding complex. Antibodies to NF-κB subunits were used for super shift assay. The arrow shows specific DNA- NF-κB complexes. The supershifted complexes are indicated by an arrowhead. (c) An NF-κB inhibitor, Bay11-7082, inhibited miR-155 expression. Real-time RT-PCR shows miR-155 expression in MT-2 cells treated with different concentration of Bay11-7082. miR-155 expression is demonstrated as a fold induction relative to that in untreated cells. Values are the mean ± SD from three separate experiments. (d) The activity of NF-κB binding to the miR-155 gene promoter was suppressed by Bay11-7082. MT-2 cells were cultured with 0, 1, 5, or 10 μM of Bay11-7082 for indicated time periods. The NF-κB binding activity on miR-155 gene promoter was determined by EMSA. Specific DNA-NF-κB subunits complexes are indicated by the arrow.
Figure 5
Figure 5
AP-1 signaling is important for miR-155 expression in HTLV-1-positive T cells. (a) DNA-binding activities of proteins to the miR-155 gene promoter in HTLV-1-positive and -negative T-cell lines was assessed by EMSA. The AP-1 oligonucleotide probe containing the AP-1-binding site from miR-155 gene was used. Arrow shows specific DNA-protein complexes. (b) The specificity of AP-1-DNA binding was analyzed in MT-2 cells. Competition assay with cold competitors of wild type probe (WT) or mutated probe (Mut) showed the specificity of the protein-DNA-binding complex. Antibodies against various AP-1 subunits were used for supershift assay. Arrow shows specific complexes of AP-1 with AP-1 probes. Arrowheads show supershifted bands.
Figure 6
Figure 6
The growth of HLTV-1-infected T cells was suppressed by inhibition of cellular miR-155 function. (a) Anti-miR-155 inhibitor (anti-miR-155) or negative control (control) was transfected into the cells (Jurkat, CCRF-CEM, or MT-2 cells). The growth of the cells was determined by trypan blue dye exclusion assay. (b) Pre-miR-155 precursor (pre-miR-155) or negative control (control) was transfected into MT-2 cells. The growth of the cells was determined by trypan blue dye exclusion assay. Mature miR-155 expression at 72 h was determined by TaqMan real-time RT-PCR. Values are the mean ± SD from three separate experiments (*P < 0.05).

References

    1. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer. 2007;7(4):270–280.
    1. Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. International Journal of Cancer. 1990;45(2):237–243.
    1. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan clinical oncology group study 9303. British Journal of Haematology. 2001;113(2):375–382.
    1. Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. Journal of Virology. 1992;66(7):4570–4575.
    1. Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the tax gene of human T-lymphotropic virus type I. Nature Medicine. 2006;12(4):466–472.
    1. Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology. 2004;1, article 20
    1. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene. 2005;24(39):5976–5985.
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
    1. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer. 2006;6(4):259–269.
    1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006;6(11):857–866.
    1. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics. 2009;10(10):704–714.
    1. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
    1. Greither T, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. International Journal of Cancer. 2010;126(1):73–80.
    1. Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene. 2006;25(46):6211–6219.
    1. Grassmann R, Jeang KT. The roles of microRNAs in mammalian virus infection. Biochimica et Biophysica Acta. 2008;1779(11):706–711.
    1. Yeung ML, Yasunaga JI, Bennasser Y, et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Research. 2008;68(21):8976–8985.
    1. Pichler K, Schneider G, Grassmann R. MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology. 2008;5, article 100
    1. Bellon M, Lepelletier Y, Hermine O, Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood. 2009;113(20):4914–4917.
    1. van den Berg A, Kroesen BJ, Kooistra K, et al. High expression of B-cell receptor inducible gene BIC in all subtypes of hodgkin lymphoma. Genes Chromosomes and Cancer. 2003;37(1):20–28.
    1. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. Journal of Pathology. 2005;207(2):243–249.
    1. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(10):3627–3632.
    1. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608–611.
    1. Haasch D, Chen YW, Reilly RM, et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cellular Immunology. 2002;217(1-2):78–86.
    1. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(18):7024–7029.
    1. Nagata K, Ohtani K, Nakamura M, Sugamura K. Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40(tax) protein in the human T-cell line, Jurkat. Journal of Virology. 1989;63(8):3220–3226.
    1. Tanaka Y, Fukudome K, Hayashi M, Takagi S, Yoshie O. Induction of ICAM-1 and LFA-3 by Tax1 of human T-cell leukemia virus type 1 and mechanism of down-regulation of ICAM-1 or LFA-1 in adult-T-cell-leukemia cell lines. International Journal of Cancer. 1995;60(4):554–561.
    1. Tanaka Y, Yoshida A, Takayama Y, et al. Heterogeneity of antigen molecules recognized by anti-tax1 monoclonal antibody Lt-4 in cell lines bearing human T cell leukemia virus type I and related retroviruses. Japanese Journal of Cancer Research. 1990;81(3):225–231.
    1. Tomita M, Tanaka Y, Mori N. MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-1-infected T-cells. International Journal of Cancer. 2010;130(10):2300–2309.
    1. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Research. 2005;33(20):e179.1–e179.9.
    1. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25(4):402–408.
    1. Tomita M, Choe J, Tsukazaki T, Mori N. The Kaposi’s sarcoma-associated herpesvirus K-bZIP protein represses transforming growth factor β signaling through interaction with CREB-binding protein. Oncogene. 2004;23(50):8272–8281.
    1. Harrod R, Tang Y, Nicot C, et al. An exposed KID-like domain in human T-cell lymphotropic virus type 1 tax is responsible for the recruitment of coactivators CBP/p300. Molecular and Cellular Biology. 1998;18(9):5052–5061.
    1. Matsumoto K, Shibata H, Fujisawa JI, et al. Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. Journal of Virology. 1997;71(6):4445–4451.
    1. Yin Q, McBride J, Fewell C, et al. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. Journal of Virology. 2008;82(11):5295–5306.
    1. Antalis TM, Godbolt D. Isolation of intact nuclei from hematopoietic cell types. Nucleic Acids Research. 1991;19(15):p. 4301.
    1. Mori N, Prager D. Transactivation of the interleukin-1α promoter by human T-cell leukemia virus type I and type II tax proteins. Blood. 1996;87(8):3410–3417.
    1. Iwai K, Mori N, Oie M, Yamamoto N, Fujii M. Human T-cell leukemia virus type 1 Tax protein activates transcription through AP-1 site by inducing DNA binding activity in T cells. Virology. 2001;279(1):38–46.
    1. Skalsky RL, Samols MA, Plaisance KB, et al. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. Journal of Virology. 2007;81(23):12836–12845.
    1. Gottwein E, Mukherjee N, Sachse C, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature. 2007;450(7172):1096–1099.
    1. Jiang J, Eun JL, Schmittgen TD. Increased expression of microRNA-155 in Epstein-Barr virus transformed lymphoblastoid cell lines. Genes Chromosomes and Cancer. 2006;45(1):103–106.
    1. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathway. Nucleic Acids Research. 2008;36(20):6608–6619.
    1. Lu F, Weidmer A, Liu CG, Volinia S, Croce CM, Lieberman PM. Epstein-Barr virus-induced miR-155 attenuates NF-κB signaling and stabilizes latent virus persistence. Journal of Virology. 2008;82(21):10436–10443.
    1. Kanezaki R, Toki T, Yokoyama M, et al. Transcription factor BACH1 is recruited to the nucleus by its novel alternative spliced isoform. Journal of Biological Chemistry. 2001;276(10):7278–7284.
    1. Mori N, Fujii M, Iwai K, et al. Constitutive activation of transcription factor AP-1 in primary adult T- cell leukemia cells. Blood. 2000;95(12):3915–3921.
    1. Lin Z, Flemington EK. miRNAs in the pathogenesis of oncogenic human viruses. Cancer Letters. 2011;305(2):186–199.
    1. Itkes A, Allegra CJ, Zajac-Kaye M. Multiprotein complexes present at the MIF motifs flanking the promoter of the human c-myc gene. FEBS Letters. 2000;474(1):23–28.
    1. Duyao MP, Kessler DJ, Spicer DB, et al. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NFκB. Journal of Biological Chemistry. 1992;267(23):16288–16291.
    1. Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121–135.

Source: PubMed

3
Iratkozz fel